| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. | |
|
Featured Story | | | Monday, June 18, 2018 A federal grand jury has indicted Theranos CEO Elizabeth Holmes and former COO Sunny Balwani for several counts of wire fraud and conspiracy to commit wire fraud. |
|
|
Top Stories Of The Week Wednesday, June 20, 2018 Patients might be hesitant to return for their second Shingrix dose if they experience side effects, according to doctors. Monday, June 18, 2018 The FDA has placed a clinical hold on Ziopharm Oncology’s phase 1 CAR-T trial. Ziopharm wants to run the study to assess CAR-T cells manufactured at the point of care, but the FDA is demanding more CMC information before allowing it to proceed. Tuesday, June 19, 2018 The data, taken from three patients, showed a 38% increase in a muscle protein that boys with DMD usually lack. Tuesday, June 19, 2018 Allergan is in the middle of making some moves to revive its struggling shares. And what’s next may depend on how some closely watched pipeline products perform in the months to come, analysts say. Monday, June 18, 2018 Researchers from King's College London designed a gene therapy that can be switched off once it has treated a spinal cord injury, addressing concerns of uncontrolled gene expression down the line. Monday, June 18, 2018 Here’s some irony for you: Pharma creative award submissions to the Cannes International Festival of Creativity are at a record low, but a bigger-than-ever lineup of pharma companies made the Lions Health short list. Tuesday, June 19, 2018 Merck won the FDA “priority review” designation for an application to expand Gardasil 9 into older populations up to 45 years old, about 10 years after the agency struck down a similar attempt for its older version of Gardasil. Wednesday, June 20, 2018 After five years of declines in the number of new drug shortages in the U.S., they jumped to 39 last year from 26 in the two preceding years. And while that is a far cry from the peak of more than 250 registered in 2011, the FDA acknowledges that many of the current shortages have been for critical drug products and “are having a tangible impact on patients.” Monday, June 18, 2018 The European contract research organization Optimapharm has expanded its operations to the U.S., opening a new office in New York City and appointing a VP for business development in the Americas. Enrollment Showcase | | | Sponsored by: Bioinformatics at UTHealth SBMI UTHealth SBMI now offers a M.S. track in clinical and translational bioinformatics. |
|
|
Resources Sponsored by: Life Science Strategy Group Take this anonymous 10-minute survey to share your thoughts on leading eClinical technology solutions and earn up to $55 honoraria. Take the survey now! Sponsored by: Blue Latitude Health Blue Latitude Health explores the commercial barriers and new stakeholder connections for pharma companies developing precision medicines, and reveals how to grasp novel opportunities in the new era of healthcare. Presented by: Patheon, part of Thermo Fisher Scientific “Faster and better” has become the mantra for biopharmaceutical companies as they face intense pressure to get therapies to market faster. Quickly proving efficacy in first-in-human (FIH) trials is a make-or-break milestone for these cash-strapped companies whose hopes hinge upon one or two molecules. Read how CDMOs are responding to this pressure. Sponsored by: DocuSign Life science companies are experiencing a significant transformation in how they bring new products to market. |
